HS-173, a novel pi3k inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Son, Mi Kwon ^a   Ryu, Ye Lim ^a   Jung, Kyung Hee ^a   Lee, Hyunseung ^a   Lee, Hee Seung ^a   Yan, Hong Hua ^a   Park, Heon Joo ^a   Ryu, Ji Kan ^a   Suh, Jun Kyu ^a   Hong, Sungwoo ^b   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ETHYL 6-(5-(PHENYLSULFONAMIDO)PYRIDIN-3-YL)IMIDAZO(1,2-A)PYRIDINE-3-CARBOXYLATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EXTRACELLULAR MATRIX; GENETICS; HUMAN; LIVER CIRRHOSIS; MALE; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MALE; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84890713835     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03470     Document Type: Article

References (37)

1. Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology. 134, 1655-1669 (2008). (Pubitemid 351615417)
2. Mormone, E., George, J. & Nieto, N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact. 193, 225-231 (2011).
3. Cohen-Naftaly, M. & Friedman, S. L. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 4, 391-417 (2011).
4. Reeves, H. L. & Friedman, S. L. Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci. 7, d808-826 (2002).
5. Maher, J. J. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis. 21, 417-426 (2001). (Pubitemid 32923769)
6. Iredale, J. P. et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology. 24, 176-184 (1996). (Pubitemid 26249431)
7. Tsukamoto, H. et al. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol. 21, S102-105 (2006). (Pubitemid 44266562)
8. Bai, T. et al. Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. Int Immunopharmacol. 15, 275-281 (2013).
9. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science. 296, 1655-1657 (2002). (Pubitemid 34579158)
10. Andre, E. et al. Expression and functional pharmacology of the bradykinin B1 receptor in the normal and inflamed human gallbladder. Gut. 57, 628-633 (2008). (Pubitemid 351579976)
11. He, Z. et al. Lipopolysaccharide induces lung fibroblast proliferation through Tolllike receptor 4 signaling and the phosphoinositide3-kinase-Akt pathway. PLoS One. 7, e35926 (2012).
12. Li, N. et al. Suppression of type I collagen expression by miR-29b via PI3K, Akt, and Sp1 pathway in human Tenon's fibroblasts. Invest Ophthalmol Vis Sci. 53, 1670-1678 (2012).
13. Miao, B. & Degterev, A. Targeting phospshatidylinositol 3-kinase signaling with novel phosphatidylinositol 3,4,5-triphosphate antagonists. Autophagy. 7, 650-651 (2011).
14. Reif, S. et al. The role of focal adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem. 278, 8083-8090 (2003). (Pubitemid 36800548)
15. Welsh, P. & Repetto, R. Revascularization of the profunda femoris artery in aortoiliac occlusive disease. Surgery. 78, 389-393 (1975).
16. Kulik, G., Klippel, A. & Weber, M. J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 17, 1595-1606 (1997). (Pubitemid 27097389)
17. Gentilini, A.,Marra, F., Gentilini, P. & Pinzani, M. Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. J Hepatol. 32, 227-234 (2000). (Pubitemid 30093901)
18. Yun, S. M. et al. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Cancer Lett. 331, 250-261 (2013).
19. Lee, H. et al. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Cancer Lett. 328, 152-159 (2013).
20. Ikejima, K. et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 122, 1399-1410 (2002). (Pubitemid 34465182)
21. Lee, J. H. et al. The use of low molecular weight heparin-pluronic nanogels to impede liver fibrosis by inhibition the TGF-beta/Smad signaling pathway. Biomaterials. 32, 1438-1445 (2011).
22. Coffer, P. J., Jin, J. & Woodgett, J. R. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J. 335, 1-13 (1998). (Pubitemid 28477043)
23. Friedman, S. L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 275, 2247-2250 (2000). (Pubitemid 30081976)
24. Son, G. et al. Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology. 50, 1512-1523 (2009).
25. Bonnet, J., Mayonove, P. &Morris, M. C. Differential phosphorylation of Cdc25C phosphatase in mitosis. Biochem Biophys Res Commun. 370, 483-488 (2008).
26. Reinhardt, H. C. & Yaffe, M. B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol. 21, 245-255 (2009).
27. Pietenpol, J. A. & Stewart, Z. A. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology. 181-182, 475-481 (2002). (Pubitemid 36015741)
28. Hirose, Y. et al. Akt activation suppresses Chk2-mediated, methylating agentinduced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res. 65, 4861-4869 (2005). (Pubitemid 40740825)
29. Nebreda, A. R.&Ferby, I. Regulation of the meiotic cell cycle in oocytes. Curr Opin Cell Biol. 12, 666-675 (2000).
30. Novo, E. et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut. 55, 1174-1182 (2006). (Pubitemid 44085687)
31. Green, D. R. & Kroemer, G. The pathophysiology of mitochondrial cell death. Science. 305, 626-629 (2004). (Pubitemid 39006738)
32. Nguyen, M. et al. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol Chem. 268, 25265-25268 (1993). (Pubitemid 23358123)
33. Zha, J. et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 87, 619-628 (1996). (Pubitemid 26386936)
34. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell. 100, 57-70 (2000). (Pubitemid 30046295)
35. Wang, Y. et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol. 53, 132-144 (2010).
36. Conte, E. et al. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts intomyofibroblasts: the role of class I P110 isoforms. PLoS One. 6, e24663 (2011).
37. Marra, F. et al. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology. 112, 1297-1306 (1997). (Pubitemid 27157544)